Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab

Rheumatology (United Kingdom)

Volumn 55, Issue 6, 2016, Pages 991-999

  Aggarwal, Rohit ^a   Oddis, Chester V ^a   Goudeau, Danielle ^a   Koontz, Diane ^a   Qi, Zengbiao ^a   Reed, Ann M ^b   Ascherman, Dana P ^c   Levesque, Marc C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Anti Jo 1; Anti SRP; Anti TIF1 and anti Mi 2 autoantibodies; Autoantibody levels; Disease activity; Myositis; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; CYCLOSPORIN A; FRUCTOSE BISPHOSPHATE ALDOLASE; IMMUNOGLOBULIN; JO 1 ANTIBODY; LACTATE DEHYDROGENASE; METHOTREXATE; MI 2 ANTIBODY; MUSCLE ENZYME; MYCOPHENOLIC ACID; PLACEBO; RITUXIMAB; SIGNAL RECOGNITION PARTICLE; TACROLIMUS; TRANSCRIPTION INTERMEDIARY FACTOR 1 GAMMA ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; AUTOANTIGEN; BIOLOGICAL MARKER; CHD4 PROTEIN, HUMAN; HISTONE DEACETYLASE; JO-1 ANTIBODY; TRANSCRIPTION FACTOR; TRIM33 PROTEIN, HUMAN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOBAL VISUAL ANALOGUE SCALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMORAL IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MANUAL MUSCLE TESTING; MUSCULOSKELETAL DISEASE ASSESSMENT; MUSCULOSKELETAL SYSTEM PARAMETERS; MYOSITIS; MYOSITIS CORE SET MEASURE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO TREATMENT; TREATMENT RESPONSE; VISUAL ANALOG SCALE; B LYMPHOCYTE; BLOOD; CHILD; DISEASE COURSE; DRUG EFFECTS; ENZYMOLOGY; IMMUNOLOGY; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; SEVERITY OF ILLNESS INDEX; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES; BIOMARKERS; CHILD; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; MIDDLE AGED; MUSCLE, SKELETAL; MYOSITIS; RITUXIMAB; SEVERITY OF ILLNESS INDEX; SIGNAL RECOGNITION PARTICLE; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84974782503     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev444     Document Type: Article

References (36)

1. Rider LG, Lachenbruch PA, Monroe JB et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum 2009;60:3425-35.
2. Miller FW, Rider LG, Chung YL et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 2001;40:1262-73.
3. Volochayev R, Csako G, Wesley R, Rider LG, Miller FW. Laboratory test abnormalities are common in polymyositis and dermatomyositis and differ among clinical and demographic groups. Open Rheumatol J. 2012;6:54-63.
4. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep 2003;5:425-30.
5. Harlow L, Fernandez I, Soejima M, Ridgway WM, Ascherman DP. Characterization of TLR4-mediated auto-antibody production in a mouse model of histidyltRNA synthetase-induced myositis. Innate Immun 2012;18:876-85.
6. Yoshida S, Akizuki M, Mimori T et al. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum 1983;26:604-11.
7. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest 1990;85:468-75.
8. Stone KB, Oddis CV, Fertig N et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56:3125-31.
9. Trallero-Araguas E, Rodrigo-Pendas JA, Selva- O'Callaghan A et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64:523-32.
10. Fujimoto M, Hamaguchi Y, Kaji K et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012;64:513-22.
11. Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res 2010;62:1328-34.
12. Benveniste O, Drouot L, Jouen F et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011;63:1961-71.
13. Aggarwal R, Bandos A, Reed AM et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol 2014;66:740-9.
14. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
15. Vincent DF, Yan KP, Treilleux I et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 2009;5:e1000575.
16. Feldman B, Wang E, Willan A, Szalai JP. The randomized placebo-phase design for clinical trials. J Clin Epidemiol 2001;54:550-7.
17. Sultan SM, Allen E, Oddis CV et al. Reliability and validity of the myositis disease activity assessment tool. Arthritis Rheum 2008;58:3593-9.
18. Rider LG, Koziol D, Giannini EH et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 2010;62:465-72.
19. Mitri GM, Lucas M, Fertig N, Steen VD, Medsger TA Jr. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9.
20. Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992;35:95-100.
21. Aggarwal R, Lucas M, Fertig N, Oddis CV, Medsger TA Jr. Anti-U3 RNP autoantibodies in systemic sclerosis. Arthritis Rheum 2009;60:1112-8.
22. Aggarwal R, Oddis CV, Goudeau D et al. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology 2014;53:433-7.
23. Aggarwal R, Oddis CV, Goudeau D et al. Anti-signal recognition particle autoantibody ELISA validation and clinical associations. Rheumatology 2015;54:1194-9.
24. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2002;28:859-90, viii.
25. Esdaile JM, Abrahamowicz M, Joseph L et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996;39:370-8.
26. Keeling SO, Landewe R, van der Heijde D et al. Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein. J Rheumatol 2007;34:623-33.
27. Soejima M, Kang EH, Gu X et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)- mediated myositis. Arthritis Rheum 2011;63:479-87.
28. Ascherman DP, Oriss TB, Oddis CV, Wright TM. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol 2002;169:7127-34.
29. Bernstein RM, Morgan SH, Chapman J et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed) 1984;289:151-2.
30. Katsumata Y, Ridgway WM, Oriss T et al. Speciesspecific immune responses generated by histidyltRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun 2007;29:174-86.
31. Wakasugi K, Schimmel P. Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem 1999;274:23155-9.
32. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-51.
33. Howard OM, Dong HF, Yang D et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196:781-91.
34. Römisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006;8:R39.
35. Aggarwal R, Oddis CV, Goudeau D et al. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. Rheumatology 2014;53:433-7.
36. Rider LG, Lee J, Jansen A et al. Defining clinically relevant changes in core set activity measures for adult and juvenile idiopathic inflammatory myopathies (IIM). Arthritis Rheum 2011;63:S89.